Upstream Bio, Inc.
Upstream Bio, Inc. (UPB): 1 pipeline candidate · ~18 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
18.3 months
D/E 0.05 · 0% dilution
Lead: Phase 2
1 candidate
N/A
0 buys · 5 sells (180d)
A transparent, data-derived signal for Upstream Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$332.0M
Cash
$96.9M
Quarterly Burn
$47.9M
Runway
18.3 mo
Revenue
$1.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| verekitug | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
142
Total value held
$405.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 8,101,563 | $72.9M |
| orbimed advisors llc | 5,693,589 | $51.2M |
| vanguard capital management llc | 3,747,148 | $33.7M |
| blackrock, inc. | 3,370,689 | $30.3M |
| enavate sciences gp, llc | 2,459,703 | $22.1M |
| woodline partners lp | 1,662,962 | $15.0M |
| y-intercept (hong kong) ltd | 1,000,631 | $9.0M |
| federated hermes, inc. | 979,758 | $8.8M |
| geode capital management, llc | 950,617 | $8.6M |
| millennium management llc | 937,323 | $8.4M |
Showing top 10 of 142 institutional holders of Upstream Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Upstream Bio, Inc.'s pipeline?
Upstream Bio, Inc. (UPB) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Upstream Bio, Inc.'s lead drug candidate?
Upstream Bio, Inc.'s most advanced tracked candidate is verekitug (Phase 2) for Chronic Obstructive Pulmonary Disease; Severe Asthma; Chronic Rhinosinusitis With Nasal Polyps.
What is Upstream Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Upstream Bio, Inc. has approximately 18.3 months of cash runway.
What is Upstream Bio, Inc.'s market capitalization?
Upstream Bio, Inc.'s market capitalization is approximately $332.0M.
Who is the CEO of Upstream Bio, Inc.?
Dr. E. Rand Sutherland M.D., M.P.H. is the chief executive officer of Upstream Bio, Inc. (UPB).
Get the full picture on Upstream Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.